Icosavax
1616 Eastlake Avenue E
Suite 208
Seattle
Washington
98102
United States
Website: http://www.icosavax.com/
30 articles about Icosavax
-
Icosavax Reports Fourth Quarter and Full Year 2021 Financial Results and Provides Corporate Update
3/30/2022
Icosavax, Inc. reported financial results for the fourth quarter and full year ended December 31, 2021 and provided a corporate update.
-
Although it was relatively quiet in COVID-19-related clinical trials, there was plenty of other clinical trial news. Here’s a look.
-
Seattle-based Icosavax’s stock plunged 50% after the company reported topline interim data from its ongoing Phase I/II COVID-19 vaccine trial.
-
Icosavax Announces Topline Interim Phase 1/2 Results for IVX-411 Against SARS-CoV-2
3/25/2022
Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, today announced topline interim results from its ongoing Phase 1/2 clinical trial of IVX-411, a VLP vaccine candidate displaying the SARS-CoV-2 receptor-binding domain (RBD).
-
Icosavax to Participate in the Cowen 42nd Annual Health Care Conference
3/2/2022
Icosavax, Inc. (Nasdaq: ICVX), a biopharmaceutical company leveraging its innovative virus-like particle (VLP) platform technology to develop vaccines against infectious diseases, today announced that the company will participate in the Cowen 42nd Annual Health Care Conference taking place virtually from March 7-9, 2022.
-
Icosavax Provides Corporate Update and Anticipated Milestones for 2022
1/7/2022
Icosavax, Inc. today provided a corporate update and shared anticipated milestones for 2022.
-
Icosavax Appoints Dr. John Shiver to Board of Directors
1/5/2022
Icosavax, Inc., a biopharmaceutical company leveraging its innovative virus-like particle platform technology to develop vaccines against infectious diseases, announced the appointment of John Shiver, Ph.D., to its Board of Directors.
-
Omega raised $650 million, which it plans to invest in life science companies in the U.S. and Europe.
-
Icosavax Reports Third Quarter 2021 Financial Results and Provides Corporate Update
11/15/2021
Icosavax, Inc., a biopharmaceutical company leveraging its innovative virus-like particle platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases, reported financial results for the third quarter ended September 30, 2021 and provided a corporate update.
-
Icosavax to Participate in Upcoming Investor Conferences - Nov 11, 2021
11/11/2021
Icosavax, Inc., a biopharmaceutical company leveraging its innovative virus-like particle platform technology to develop vaccines against infectious diseases, with an initial focus on life-threatening respiratory diseases, announced that Adam Simpson, Chief Executive Officer of Icosavax, will participate in two upcoming investor conferences.